Roles of micro<scp>RNA</scp>s in psoriasis: Immunological functions and potential biomarkers

Liu, Qing; Wu, Ding Hong; Han, Ling; Deng, Jing Wen; Zhou, Li; He, Rui; Lu, Chuan Jian; Mi, Qing Sheng

doi:10.1111/exd.13249

Cited by 77 publications

(75 citation statements)

References 105 publications

(209 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…18,19 At present, several biomarkers reflecting severity/activity of psoriasis and response to biologic therapy have been proposed. These biomarkers include genotypes of human leukocyte antigen, cytokine-related genes and inflammation signal-related genes, 20,21 miRNA, 22 serum proteins, 23 such as C-reactive protein, and cytokine-related inflammation and leucine-rich a2-glycoprotein. 24 Among them, neutrophil : lymphocyte ratio can be easily and regularly measured in daily clinical examination.…”

Section: Discussionmentioning

confidence: 99%

Alteration of serum thymus and activation‐regulated chemokine level during biologic therapy for psoriasis: Possibility as a marker reflecting favorable response to anti‐interleukin‐17A agents

Shibuya

Honma

Iinuma

et al. 2018

The Journal of Dermatology

View full text Add to dashboard Cite

Biologics show great efficacy in treating psoriasis, a chronic inflammatory skin disease. The high cost and side-effects of biologics, dose-reduction, elongation of administration interval and suspension are possible options. However, there has been no reliable biomarker we can use when we consider these moderations in therapy. This study was conducted to test the possibility of using serum thymus and activation-regulated chemokine (TARC) level as an indicator for step down of biologic therapy. Serum TARC level was measured in 70 psoriatic patients at Asahikawa Medical University, and a correlation of TARC and severity of skin lesions was analyzed. Referring to serum TARC level, psoriatic patients can be divided into two groups. One is a population in which serum TARC level is positively correlated with severity of skin lesions, and the other is a population with low psoriatic severity and high TARC level. Serum TARC level was higher in the group that achieved PASI-clear with biologics than in the group which did not achieve PASI-clear. Among biologics, the group treated with secukinumab, an anti-interleukin (IL)-17A agent, showed significantly higher TARC level compared with the group treated with anti-tumor necrosis factor agents. In certain populations achieving PASI-clear, serum TARC level may be a potent marker reflecting better response to IL-17A inhibitors, and in this case step down of treatment for psoriasis is possible.

show abstract

Section: Discussionmentioning

confidence: 99%

Alteration of serum thymus and activation‐regulated chemokine level during biologic therapy for psoriasis: Possibility as a marker reflecting favorable response to anti‐interleukin‐17A agents

Shibuya

Honma

Iinuma

et al. 2018

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…Similar to long non‐coding RNAs, miRNAs are deregulated in psoriasis skin lesions (s14), reviewed in the article by Liu et al. in Experimental Dermatology . In our initial study, we found a clear separation of psoriasis skin from healthy skin or atopic eczema skin based on miRNA profiles, and identified a tissue‐specific miRNA, miR‐203, with high expression in the skin .…”

mentioning

confidence: 70%

“…Advances in technology have allowed the detection of an increasing number of differentially expressed miRNAs by RNA sequencing, as well as the detection of miRNAs even in archived material (s16, s18). The different methods to analyze miRNA expression are well described and compared in the review article by Liu et al …”

mentioning

confidence: 99%

“…As miRNAs are deregulated in psoriasis skin, it is conceivable that this could be reflected in the circulation. Indeed, several miRNAs have been suggested as biomarkers in psoriasis, with changes in their levels reflecting disease activity or response to therapy (s23‐s25) . While diagnostic markers of psoriasis may be useful in a limited patient group, a more important medical need would be the identification of biomarkers for prognosis and response to treatments.…”

mentioning

confidence: 99%

See 1 more Smart Citation

The expanding microRNA world in psoriasis

Sonkoly

2017

Experimental Dermatology

View full text Add to dashboard Cite

Since their discovery in the early 1990s, microRNAs (miRNAs), small, non-protein-coding RNAs with regulatory functions, have emerged from being a peculiarity in worms to abundant regulators of gene expression in nearly all organisms. There are more than 2500 miRNAs (miRBase 21, www.mirbase.org) in human, and the majority of proteincoding genes are thought to be regulated by miRNAs. Accordingly, miRNAs have been implicated in nearly all biological processes, in particular stem cell differentiation, development, the regulation of signalling pathways and defining cell identity.[1]Early studies with the ablation of all miRNAs by deleting Dicer, a key enzyme in the biogenesis of miRNAs, highlighted the role of miRNAs in skin development: mice with impaired biogenesis of miRNAs were not viable due to severe defects in skin structure.[2] Soon afterwards, individual miRNAs orchestrating epidermal differentiation and hair follicle development were identified, [3] and miRNAs were implicated in inflammatory and malignant skin diseases by identification of disease-specific miRNAs in psoriasis (s1), [4] atopic dermatitis (s2), delayed-type hypersensitivity reactions (s3), cutaneous T-cell lymphomas (s4), and basal (BCC) (s5) and squamous cell carcinomas (SCC) (s6, s7). Of particular interest, a miRNA with skin-restricted expression profile, miR-203, was identified (s8-s10) [4] , which regulates keratinocyte differentiation and proliferation and acts as a tumor suppressor.Psoriasis is a chronic inflammatory skin disease in which the disturbed interaction of keratinocytes and immune cells leads to a vicious circle of chronic inflammation. Are the deregulated miRNAs in psoriasis skin a cause or consequence of chronic skin inflammation? To answer this question, several K E Y W O R D Sbiomarker, microRNA, non-coding RNA, psoriasis, skin

show abstract

“…A string of differentially expressed microRNAs remains in the focus of psoriasis biology . As reviewed by Liu et al . in the current issue, they are also promising biomarkers.…”

mentioning

confidence: 99%